MappBio News

Most recent news

Researchers develop Marburg virus treatment effective five days after infection

5 Apr No Comments admin Press Releases

Contact: Donna Ramirez donna.ramirez@utmb.edu 409-772-8791 FOR IMMEDIATE RELEASE April 5, 2017 Virus causes hemorrhagic fever often leading to death April 5, 2017 – GALVESTON, Texas – An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to

LeafBio Announces NEJM Publication of ZMapp™ Clinical Trial

13 Oct No Comments admin Press Releases

Contact: Kerry Lion klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE October 12, 2016   Therapy to Treat Ebola Shows Promise October 12, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today that results from the PREVAIL II clinical trial of ZMapp™ for treatment of Ebola

Mapp Bio Receives HHS Funding for Expanded Access Protocol for Ebola Treatment

8 Aug No Comments admin Press Releases

Contact: Perry Sacks psacks@skdknick.com 202-464-6611 FOR IMMEDIATE RELEASE August 8, 2016   Funds Will Allow Ebola Patients Expanded Access to Experimental Treatment August 8, 2016 – SAN DIEGO – Today, Mapp Biopharmaceutical, Inc. (Mapp Bio) announced it has received funding from Biomedical Advanced Research and Development Authority (BARDA), part of

LeafBio Announces Conclusion of ZMapp™ Clinical Trial

23 Feb No Comments admin Press Releases

Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE February 23, 2016   LeafBio Announces Conclusion of ZMapp™ Clinical Trial Therapy to Treat Ebola Shows Promise February 23, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today results from the Prevail II clinical trial

Clinical Trials Begin on Antibody-based Prevention of HIV and Genital Herpes

7 Jan No Comments admin Press Releases

Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE January 07, 2016   Clinical Trials Begin on Antibody-based Prevention of HIV and Genital Herpes Leaf Bio’s MB66 Developed as Multipurpose Prevention Technology January 7, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today that

ZMapp™ is Granted Orphan Medicinal Product Designation by the EMA

15 Oct No Comments admin Press Releases

Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE October 15, 2015   ZMapp™ is Granted Orphan Medicinal Product Designation by the EMA Status May Enable Faster Approval of ZMapp™ October 15, 2015 – SAN DIEGO – LeafBio, Inc. (LeafBio), the commercial arm of Mapp Biopharmaceutical, Inc. (Mapp), announced today that

ZMapp™ is Granted Fast Track Status by the FDA

17 Sep No Comments admin Press Releases

Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE September 17, 2015   ZMapp™ is Granted Fast Track Status by the FDA Status May Enable Faster Approval of ZMapp™ September 17, 2015 – SAN DIEGO – LeafBio, Inc. (LeafBio), the commercial arm of Mapp Biopharmaceutical, Inc. (Mapp), announced today that the

Government of Canada strengthens Ebola preparedness for Canadians

10 Jun No Comments admin Press Releases

Public Health Agency of Canada Ottawa, ON FOR IMMEDIATE RELEASE June 10, 2015 Government of Canada strengthens Ebola preparedness for Canadians Contract signed to manufacture ZMappTM to help protect Canadians The Honourable Rona Ambrose, Minister of Health, and Canada’s Chief Public Health Officer, Dr. Gregory Taylor, today announced a $4.5

© 2016 Mapp Biopharmaceautical - Leaf Bio. All Rights Reserved.